| P50 | author | Andreas Jonsson | Q89215390 |
| P2093 | author name string | Peter Falk | |
| | Claes Hjalmarsson | |
| | Marie-Lois Ivarsson | |
| P2860 | cites work | Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications | Q33692926 |
| | Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. | Q36611209 |
| | Assessing the value of matrix metalloproteinase 9 (MMP9) in improving the appropriateness of referrals for colorectal cancer | Q36746744 |
| | The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. | Q36846901 |
| | Circulating matrix metalloproteinases and their inhibitors in hypertension. | Q37975870 |
| | Is serum matrix metalloproteinase 9 a useful biomarker in detection of colorectal cancer? Considering pre-analytical interference that may influence diagnostic accuracy | Q42424812 |
| | Prognostic role of tumor-associated proteases in colorectal cancer. | Q44182376 |
| | Reference intervals of plasma matrix metalloproteinases 2, 3, and 9 and serum asymmetric dimethylarginine levels | Q85550791 |
| | Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities | Q46541397 |
| | Impact of Blood Sampling on the Circulating Matrix Metalloproteinases 1, 2, 3, 7, 8, and 9 | Q62632426 |
| | Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma | Q62632457 |
| | Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases | Q62632476 |
| | Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes | Q62632482 |
| | Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood | Q78338951 |
| | Use of plasma MMP‐2 and MMP‐9 levels as a surrogate for tumour expression in colorectal cancer patients | Q79103460 |
| | Gelatinase concentrations and zymographic profiles in human breast cancer: matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: the coagulation/fibrinolysis pathways alter the r | Q79812081 |
| | Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution | Q80087614 |
| | Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients | Q80288717 |
| | Measurement of matrix metalloproteinases in serum of patients with melanoma: snarled in technical pitfalls | Q80404818 |
| | Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer | Q81127482 |
| | Positive correlations between serum and plasma matrix metalloproteinase (MMP)-2 or MMP-9 levels in disease conditions | Q84165610 |
| | Release of matrix metalloproteinases-1 and -2, but not -9, from activated platelets measured by enzyme-linked immunosorbent assay | Q84558347 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International | Q42553662 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 703-706 | |
| P577 | publication date | 2016-05-17 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Levels of matrix metalloproteinases differ in plasma and serum - aspects regarding analysis of biological markers in cancer | |
| P478 | volume | 115 | |